ChromaDex (NASDAQ:CDXC) Given New $8.10 Price Target at LADENBURG THALM/SH SH

ChromaDex (NASDAQ:CDXC) had its price objective raised by LADENBURG THALM/SH SH from $6.80 to $8.10 in a research note published on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other analysts also recently weighed in on the stock. Roth Mkm upped their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. StockNews.com raised shares of ChromaDex from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 24th.

ChromaDex Trading Up 52.7 %

Shares of NASDAQ CDXC opened at $8.55 on Wednesday. The firm has a fifty day simple moving average of $5.68 and a two-hundred day simple moving average of $5.13. The firm has a market capitalization of $653.07 million, a PE ratio of 855.86 and a beta of 2.21. ChromaDex has a 12 month low of $1.57 and a 12 month high of $9.18.

Insider Activity at ChromaDex

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the sale, the director now directly owns 244,179 shares of the company’s stock, valued at approximately $1,511,468.01. This represents a 13.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 9.64% of the stock is currently owned by insiders.

Institutional Trading of ChromaDex

Institutional investors have recently bought and sold shares of the company. USA Financial Formulas purchased a new stake in ChromaDex during the 4th quarter valued at about $25,000. State of Wyoming purchased a new stake in ChromaDex during the 4th quarter valued at about $39,000. Mercer Global Advisors Inc. ADV purchased a new stake in ChromaDex during the 4th quarter valued at about $53,000. Truist Financial Corp purchased a new stake in ChromaDex during the 4th quarter valued at about $54,000. Finally, FMR LLC purchased a new stake in shares of ChromaDex during the 3rd quarter valued at about $55,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.